KR20180082734A - Cream modeling mask pack for epidermal moisturing composition comprising chlorophyll derivatives and preparation method of the same - Google Patents
Cream modeling mask pack for epidermal moisturing composition comprising chlorophyll derivatives and preparation method of the same Download PDFInfo
- Publication number
- KR20180082734A KR20180082734A KR1020170003965A KR20170003965A KR20180082734A KR 20180082734 A KR20180082734 A KR 20180082734A KR 1020170003965 A KR1020170003965 A KR 1020170003965A KR 20170003965 A KR20170003965 A KR 20170003965A KR 20180082734 A KR20180082734 A KR 20180082734A
- Authority
- KR
- South Korea
- Prior art keywords
- chlorophyll
- mask pack
- pheophytin
- cream
- composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- ATNHDLDRLWWWCB-AENOIHSZSA-M chlorophyll a Chemical class C1([C@@H](C(=O)OC)C(=O)C2=C3C)=C2N2C3=CC(C(CC)=C3C)=[N+]4C3=CC3=C(C=C)C(C)=C5N3[Mg-2]42[N+]2=C1[C@@H](CCC(=O)OC\C=C(/C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)[C@H](C)C2=C5 ATNHDLDRLWWWCB-AENOIHSZSA-M 0.000 title claims abstract description 56
- 239000000203 mixture Substances 0.000 title claims abstract description 24
- 239000006071 cream Substances 0.000 title claims abstract description 21
- 238000002360 preparation method Methods 0.000 title 1
- 238000004519 manufacturing process Methods 0.000 claims abstract description 9
- 230000003020 moisturizing effect Effects 0.000 claims abstract description 9
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 10
- 239000011734 sodium Substances 0.000 claims description 10
- 229910052708 sodium Inorganic materials 0.000 claims description 10
- 108010020346 Polyglutamic Acid Proteins 0.000 claims description 9
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 9
- 229920000370 gamma-poly(glutamate) polymer Polymers 0.000 claims description 9
- 239000003795 chemical substances by application Substances 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 7
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 6
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 claims description 6
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 6
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 6
- 229940015975 1,2-hexanediol Drugs 0.000 claims description 5
- NCZPCONIKBICGS-UHFFFAOYSA-N 3-(2-ethylhexoxy)propane-1,2-diol Chemical compound CCCCC(CC)COCC(O)CO NCZPCONIKBICGS-UHFFFAOYSA-N 0.000 claims description 5
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims description 5
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 5
- 235000010443 alginic acid Nutrition 0.000 claims description 5
- 229920000615 alginic acid Polymers 0.000 claims description 5
- 239000004359 castor oil Substances 0.000 claims description 5
- 235000019438 castor oil Nutrition 0.000 claims description 5
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims description 5
- 229940100524 ethylhexylglycerin Drugs 0.000 claims description 5
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 5
- FHKSXSQHXQEMOK-UHFFFAOYSA-N hexane-1,2-diol Chemical compound CCCCC(O)CO FHKSXSQHXQEMOK-UHFFFAOYSA-N 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 239000000843 powder Substances 0.000 claims description 5
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 claims description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 3
- 239000005909 Kieselgur Substances 0.000 claims description 3
- 239000008103 glucose Substances 0.000 claims description 3
- 239000008213 purified water Substances 0.000 claims description 3
- 239000000377 silicon dioxide Substances 0.000 claims description 3
- RYCLIXPGLDDLTM-UHFFFAOYSA-J tetrapotassium;phosphonato phosphate Chemical compound [K+].[K+].[K+].[K+].[O-]P([O-])(=O)OP([O-])([O-])=O RYCLIXPGLDDLTM-UHFFFAOYSA-J 0.000 claims description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 claims description 2
- 229960001777 castor oil Drugs 0.000 claims description 2
- 238000000034 method Methods 0.000 claims 1
- 239000002537 cosmetic Substances 0.000 abstract description 2
- 229930002875 chlorophyll Natural products 0.000 description 28
- 235000019804 chlorophyll Nutrition 0.000 description 28
- 210000004027 cell Anatomy 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 210000003491 skin Anatomy 0.000 description 7
- 230000036572 transepidermal water loss Effects 0.000 description 6
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 5
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 5
- 239000008280 blood Substances 0.000 description 5
- 210000004369 blood Anatomy 0.000 description 5
- 229910052749 magnesium Inorganic materials 0.000 description 5
- 239000011777 magnesium Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 206010028980 Neoplasm Diseases 0.000 description 4
- 201000011510 cancer Diseases 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 150000004032 porphyrins Chemical class 0.000 description 4
- 241000196324 Embryophyta Species 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- 239000003963 antioxidant agent Substances 0.000 description 3
- 230000003078 antioxidant effect Effects 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 239000013522 chelant Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000004060 metabolic process Effects 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 230000029553 photosynthesis Effects 0.000 description 3
- 238000010672 photosynthesis Methods 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 102000016938 Catalase Human genes 0.000 description 2
- 108010053835 Catalase Proteins 0.000 description 2
- KAESVJOAVNADME-UHFFFAOYSA-N Pyrrole Chemical compound C=1C=CNC=1 KAESVJOAVNADME-UHFFFAOYSA-N 0.000 description 2
- 102000019197 Superoxide Dismutase Human genes 0.000 description 2
- 108010012715 Superoxide dismutase Proteins 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 210000003763 chloroplast Anatomy 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- WCDDVEOXEIYWFB-VXORFPGASA-N (2s,3s,4r,5r,6r)-3-[(2s,3r,5s,6r)-3-acetamido-5-hydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5,6-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@@H]1C[C@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](C(O)=O)O[C@@H](O)[C@H](O)[C@H]1O WCDDVEOXEIYWFB-VXORFPGASA-N 0.000 description 1
- 208000002874 Acne Vulgaris Diseases 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 235000017166 Bambusa arundinacea Nutrition 0.000 description 1
- 235000017491 Bambusa tulda Nutrition 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 101100284769 Drosophila melanogaster hemo gene Proteins 0.000 description 1
- 208000002197 Ehlers-Danlos syndrome Diseases 0.000 description 1
- 108010024636 Glutathione Proteins 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 244000082204 Phyllostachys viridis Species 0.000 description 1
- 235000015334 Phyllostachys viridis Nutrition 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 206010000496 acne Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000003712 anti-aging effect Effects 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000000840 anti-viral effect Effects 0.000 description 1
- 239000003173 antianemic agent Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 239000011425 bamboo Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 231100000357 carcinogen Toxicity 0.000 description 1
- 239000003183 carcinogenic agent Substances 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 210000002421 cell wall Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 235000019805 chlorophyllin Nutrition 0.000 description 1
- 229940099898 chlorophyllin Drugs 0.000 description 1
- 238000001784 detoxification Methods 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000003925 fat Substances 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000005188 flotation Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 229960003180 glutathione Drugs 0.000 description 1
- 239000001056 green pigment Substances 0.000 description 1
- 150000003278 haem Chemical class 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 231100000283 hepatitis Toxicity 0.000 description 1
- 229940014041 hyaluronate Drugs 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000003908 liver function Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000013081 microcrystal Substances 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000010606 normalization Methods 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 235000017807 phytochemicals Nutrition 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 229930000223 plant secondary metabolite Natural products 0.000 description 1
- 150000004033 porphyrin derivatives Chemical class 0.000 description 1
- 238000001243 protein synthesis Methods 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000007651 self-proliferation Effects 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 210000001082 somatic cell Anatomy 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 210000002377 thylakoid Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000014616 translation Effects 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/0212—Face masks
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
- A61K8/04—Dispersions; Emulsions
- A61K8/06—Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Birds (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Dispersion Chemistry (AREA)
- Cosmetics (AREA)
Abstract
본 발명은 엽록소 유도체 (Zn-Pheophytin)가 함유된 크림 모델링 마스크팩 조성물 및 그 제조방법에 관한 것으로 우수한 인체 피부 보습효과가 있는 엽록소 유도체 (Zn-Pheophytin)가 함유된 피부보습용 화장료를 제공하는 뛰어난 효과가 있다.The present invention relates to a cream modeling mask pack composition containing a chlorophyll derivative (Zn-Pheophytin) and a method for producing the cream modeling mask pack composition, and relates to a cosmetic composition for skin moisturizing which contains a chlorophyll derivative (Zn-Pheophytin) It is effective.
Description
본 발명은 엽록소 유도체(Zn-Pheophytin)가 함유된 크림 모델링 피부보습용 마스크팩 조성물 및 그 제조방법에 관한 것이다.The present invention relates to a skin mask moisturizing mask pack composition containing a chlorophyll derivative (Zn-Pheophytin) and a method for producing the same.
엽록소 (葉綠素, Chlorophyll)는 5㎛ 내외의 밀납상의 청홍색 미세 결정으로, 식물 세포 내 엽록체에 존재하는 녹색 색소를 말한다. 또한 엽록소는 광합성의 핵심 분자로 태양 에너지를 지표의 화학 에너지로 전환하는 작용을 한다. 즉 광합성을 통해 탄수화물을 만들어 식물에 공급하는 역할을 하며, 보통 식물의 잎에 가장 많고, 마그네슘을 가진 chelate form을 형성한다. Chlorophyll (chlorophyll) is a waxy cyanite microcrystal of about 5 μm and refers to the green pigment present in chloroplasts in plant cells. Chlorophyll is also a key molecule in photosynthesis, which converts solar energy into chemical energy on the surface. In other words, it plays a role of producing carbohydrates through photosynthesis and supplying them to plants. It forms the chelate form with the most magnesium in the leaves of plants.
엽록소는 엽록체 (Chloroplast)의 내, 외벽 속에 stroma, grana, thylakoid 등 수개층의 단단한 막으로 감싸여 있으므로 직접 인체에 작용하는 것이 불가능하기 때문에 단체분자 형태로 추출해서 섭취해야 정상 작용이 가능하다. Since chlorophyll is wrapped in several layers of stroma, grana, and thylakoid in chloroplast inner and outer walls, it can not act directly on the human body.
엽록소의 구조는 도1에 기재하였다. 엽록소는 원판상의 단백질과 지방질이 수개 층으로 구성된 다층 구조를 이루고 있다. 머리부 (Head)는 친수성으로 porphyrin에는 pyrrole과 chelate form으로 연결된 마그네슘 원자가 존재한다. 꼬리부(Tail)에는 친유성의 Lipoid와 pythol이 결합되어 있고, 자연 상태의 엽록소에는 pythol이 반드시 결합되어 있는데, 이는 천연 엽록소를 구별할 수 있는 가장 큰 특징 중 하나이다. The structure of the chlorophyll is shown in Fig. Chlorophyll has a multilayered structure consisting of several layers of proteins and fats on the disc. The head is hydrophilic and the porphyrin has a magnesium atom linked to the pyrrole and the chelate form. In the tail, lipophilic lipids and pythol are combined, and natural chlorophyll is bound to pythol, which is one of the most distinguishing characteristics of natural chlorophyll.
엽록소의 구조는 초미립자로 20만배 이상의 고배율의 전자 현미경을 통해 확인 가능하다. 머리부(Head)는 Magnesium chelate 구조를 가진 Porphyrin Ring으로 구성되어 있으며, 친수성을 나타낸다. 꼬리부는 체세포의 지질 단백막과 쉽게 결합할 수 복합체로 존재하며, 친유성을 나타내고 친수성과 친유성을 모두 가진 계면활성 분자로 막 구조에 접근할 수 있는 촉매효과를 나타낸다.The structure of the chlorophyll is superfine and can be confirmed by electron microscopy at a high magnification of over 200,000 times. The head is composed of a Porphyrin Ring with a Magnesium chelate structure and exhibits hydrophilicity. The tail is present as a complex that can easily bind to the lipid protein membrane of somatic cells. It exhibits a lipophilic property and is a surfactant molecule having both hydrophilic and lipophilic properties.
엽록소의 기능은 광합성을 통해 태양 복사 에너지를 전기 에너지로 전환하고 RNA와 DNA를 모두 보유하여 독자적인 단백질 합성 및 자기 증식 능력 보유하며 체내 유리 라디칼(Free Radical)과 결합하여 노화 반응 억제하고 글루타치온을 환원형으로 활성화하여 신진 대사의 정상화하는 것으로 보고되고 있다.The function of chlorophyll is to convert solar radiation energy into electric energy through photosynthesis and possess unique protein synthesis and self-proliferation ability by possessing both RNA and DNA. It is combined with Free Radical to inhibit aging reaction and reduce glutathione And it is reported that normalization of metabolism is activated.
엽록소는 1900년대 초 연구가 본격화된 후 많은 연구가들에 의해 다양한 연구 및 임상실험으로 엽록소가 인체에 미치는 영향이 입증되었는데 먼저 엽록소는 새로운 피를 만드는 조혈작용과 피를 맑게 하는 청혈작용을 한다고 보고된바 있고 혈액인 헤모(Hemo)의 화학구조와 매우 비슷하며 실제로 철 클로로필린 등은 조혈제로 사용되고 있다. Chlorophyll has been proved to be effective in various researches and clinical trials by many researchers after the start of research in the early 1900's. Chlorophyll has been reported to have hematopoietic effect to make new blood and purulent blood to clear blood It is very similar to the chemical structure of Hemo, which is blood, and iron chlorophyllin is actually used as hematopoietic agent.
또한 Catalase 효소와도 유사하여 엽록소, 헤모는 모두 porphrin체로 되어 있으며, 이는 하기와 같다. It is also similar to the catalase enzyme, so that chlorophyll and hemoglobin are both porphrins.
포르피린 (Porphyrin)은 Pyrrole 구조 4개와 메칠기 4개가 결합하여 생긴 포르핀 유도체로 이들 3종 물질의 분자 구조는 매우 유사하며, 차이점은 엽록소의 경우 중앙 핵에 마그네슘(Mg)을, Heme과 Catalase의 경우 중앙 핵에는 철(Fe)이 함유되어 있다. 따라서 초식동물이 풀을 먹으면 동물의 장 융모에 많이 존재하는 철이 엽록소 중앙의 마그네슘과 치환되기 때문에 초식 동물들이 그 생명을 유지할 수 있다고 보고 있다. Porphyrin is a porphyrin derivative formed by combining 4 pyrrole structures and 4 methyl groups. The molecular structure of these three materials is very similar. The difference is that chlorophyll has magnesium (Mg) in the central nucleus, Heme and Catalase The central core contains iron (Fe). Therefore, when a herbivorous animal eats grass, it is believed that the herbivorous animals are able to sustain their lives because the iron present in the intestinal villi of animals is replaced with magnesium in the center of the chlorophyll.
또, 엽록소는 인체에 염증을 일으키는 발염 물질과 결합하여 그 물질을 중화시키는 항염작용을 하는데 이때 포르피린 핵이 여러 물질들과 결합이 용이하므로 발염 물질과의 결합을 통해 해독, 중화시키는 것으로 알려져 있다. 또한 간 기능 강화를 통해 해독력을 높여 유독 성분이 체내에 머무르지 못하게 한다. 간의 해독 능력이 높아지면 정혈 작용은 자연스럽게 수반된다고 본다. It is known that chlorophyll binds to the body's inflammatory substance and neutralizes the substance. It is known that the porphyrin nucleus is easy to bind with various substances, so it can be decrypted and neutralized through binding with the flotation material. It also enhances the detoxification ability by strengthening liver function, so that toxic components do not stay in the body. If the ability to decipher liver is increased, I think that the blood flow is naturally accompanied.
인체내 활성산소에 의해 프리 라디칼 (Free Radical)이 발생되어 축적되면 노화를 촉진하는 과산화지질이 만들어 지는데, 이 때 엽록소는 체내에 축적된 활성산소를 제거할 수 있는 SOD(Superoxide Dismutase) 가 풍부하여 활성산소를 효과적으로 제거함으로써 항산화, 항노화 작용을 통해 젊음을 유지하고 신체의 균형을 유지하는데 도움을 준다고 사료된다.When free radicals are generated and accumulated by active oxygen in the body, lipid peroxidation which promotes aging is produced. At this time, chlorophyll is abundant in superoxide dismutase (SOD) which can remove active oxygen accumulated in the body By effectively removing active oxygen, antioxidant and anti-aging action are thought to help maintain youthful balance and maintain body balance.
이밖에 엽록소는 혈액을 정화함과 동시에 발암 물질을 중화시켜 손상된 세포를 재생시키고, 암 세포나 바이러스의 발생을 억제하며, 돌연변이에 의한 암 발생을 억제시킨다. 이와 관련해서 항암제는 암세포 외 건강한 세포에도 반응하지만 엽록소는 암세포에만 선택적으로 반응한다는 특이성에 대한 연구 보고도 있다. In addition, chlorophyll cleanses blood and neutralizes carcinogens, regenerating damaged cells, inhibiting the development of cancer cells and viruses, and inhibiting the development of cancer by mutation. In this regard, anti-cancer drugs react to cancer cells as well as healthy cells, but there is also a report on the specificity of chlorophyll that selectively reacts with cancer cells.
또, 엽록소는 여러 가지 면역 성분과 세포 증식을 촉진하여 치유 능력 개선 및 세포의 재생능력을 향상시킨다. 엽록소는 세포벽을 두껍게 만들어서 외부 유해 환경으로부터 건강한 세포를 유지하게 하므로 면역력 증강에 도움을 줄 뿐만 아니라, 생리대사, 질소 대사를 촉진하여 표피에 침착된 색소를 제거하고, 맑고 투명하며 촉촉하고 탄력있는 피부와 개선 및 제균 작용과 섬유 아세포의 성장을 촉진하여 여드름과 같은 피부 트러블을 예방하고 보습력이 높은 피부를 만들게 한다. Chlorophyll promotes various immune components and cell proliferation and improves healing ability and cell regeneration ability. Chlorophyll thickens the cell wall and keeps healthy cells from external harmful environment. It not only helps to increase immunity, but also promotes physiology, nitrogen metabolism, removes the pigment deposited on the epidermis, and is transparent, moist and elastic skin And improves and eliminates the bacteria and promotes the growth of fibroblasts to prevent skin troubles such as acne and make the skin with high moisture.
이상 보고된 효능 외에도 엽록소는 혈구수 증가, 혈압 강하, 간염 예방에 도움, 천식 완화, 상처 치유에 도움, 인후염 완화, 항바이러스 효과, 항알레르기 작용 및 신진 대사 촉진 등에 도움을 주는 것으로 알려져 있다. In addition to the reported efficacy, chlorophyll is known to help increase blood count, lower blood pressure, help prevent hepatitis, relieve asthma, help heal wounds, relieve sore throat, antiviral effect, antiallergic action and promote metabolism.
반면 엽록소는 그 자체로서 불안정하며 추출 및 정제 과정에서 효능이 소실될 수 있기 때문에 최근 엽록소 유도체에 대한 연구가 진행중이다. 엽록소 유도체 (Chlorophyll Derivatives)는 엽록소 중심에 존재하는 Mg2+ 대신 Zn2+, Fe2+, Cu2+ 등의 2가 금속이온이 치환된 것을 의미한다(Zn-pheophytin, Fe-pheophytin, Cu-pheophytin 등). 엽록소 유도체의 경우 과거에는 엽록소의 불안정성을 해결하기 위한 방향으로 연구가 진행되었으나, 최근에는 엽록소 유도체가 엽록소에 비해 항산화능이 더 뛰어나다는 결과가 보고되어 이들에 대한 연구가 진행중이다.On the other hand, chlorophyll is in itself unstable and its efficacy can be lost in the extraction and purification process. Chlorophyll Derivatives refers to the substitution of divalent metal ions such as Zn2 +, Fe2 +, Cu2 +, etc. instead of Mg2 + in the center of chlorophyll (Zn-pheophytin, Fe-pheophytin and Cu-pheophytin). In the past, chlorophyll derivatives have been investigated in order to solve the instability of chlorophyll. Recently, however, chlorophyll derivatives have been reported to have better antioxidant ability than chlorophyll.
이로 본 연구에서는 엽록소에 비해 장기 안정도 및 항산화능이 더 우수한 엽록소 유도체(Zn-Pheophytin)를 크림 모델링 마스크팩에 적용하여 이들의 보습력을 확인하였다. In this study, chlorophyll derivative (Zn-Pheophytin), which has better long-term stability and antioxidant ability than chlorophyll, was applied to a cream modeling mask pack to confirm the moisture resistance.
본 발명과 관련된 선행기술로는 대한민국 등록특허 10-1503577호가 공지되어 있으나 이는 천연 다시마를 이용한 마스크팩의 제조방법에 관한 것으로 지금까지 엽록소 유도체(Zn-Pheophytin)가 함유된 크림 모델링 마스크팩 조성물 및 이를 이용한 마스크팩의 제조방법에 대하여는 공지된 바 없다.
Korean Patent No. 10-1503577 discloses a prior art related to the present invention, but it relates to a method of manufacturing a mask pack using natural sea tangle and a cream modeling mask pack composition containing a chlorophyll derivative (Zn-Pheophytin) There is no known method for producing the mask pack.
따라서, 본 발명의 목적은 피토케미칼의 일종인 엽록소 유도체(Zn-Pheophytin)를 함유하는 크림 모델링 피부보습용 마스크팩 조성물을 제공하는 데 있다. 본 발명의 다른 목적은 상기 조성물의 제조방법을 제공한다.
Accordingly, an object of the present invention is to provide a mask pack composition for cream moisturizing skin which contains a chlorophyll derivative (Zn-Pheophytin), which is a kind of phytochemicals. Another object of the present invention is to provide a method for producing the composition.
본 발명의 상기 목적은 Glucose, Calcium Sulfate, Diatomaceous Earth, Silica 및 Tetrapotassium Pyrophosphate를 핸슬믹서에 넣고 혼합 및 교반하여 파우더제를 수득하는 단계와;The above object of the present invention can be achieved by a method for producing a powdery composition, comprising the steps of: adding Glucose, Calcium Sulfate, Diatomaceous Earth, Silica and Tetrapotassium Pyrophosphate into a Handsmixer, mixing and stirring to obtain a powder agent;
한편 이와 별도로 계량한 정제수에 점증제 알진(Algin)을 먼저 첨가하고 Agi-mixer로 균일하게 혼합하여 점증여부를 확인하는 단계와; 상기 별도의 혼합단계를 통하여 얻은 점증물에 부틸렌글리콜(Butylene Glycol), PEG-60 Hydrogenated Castor Oil, 1,2-Hexanediol, 에틸헥실글리세린(Ethylhexylglycerin), Disodium EDTA 및 보습제인 Sodium Hyaluronate 또는 Sodium Polyglutamate를 첨가한 후 균일하게 분산시키는 단계와; 상기 분산단계에서 얻은 혼합물에 엽록소 유도체(Zn-Pheophytin)를 첨가하여 분산한 후 점도가 40,000cps 이상인 크림제를 수득하는 단계를 통해 달성하였다.On the other hand, the step of adding incremental algin to the purified water separately and mixing it uniformly with an Agi-mixer to ascertain whether it is growing; PEG-60 Hydrogenated Castor Oil, 1,2-Hexanediol, Ethylhexylglycerin, Disodium EDTA, and Sodium Hyaluronate or Sodium Polyglutamate, which are moisturizing agents, are added to the incremental product obtained through the separate mixing step. Adding and dispersing the mixture uniformly; (Zn-Pheophytin) was added to the mixture obtained in the dispersion step and dispersed to obtain a cream agent having a viscosity of 40,000 cps or more.
본 발명은 엽록소 유도체(Zn-Pheophytin)를 함유하는 크림 모델링 마스크팩 조성물은 보습효과가 뛰어난 효과가 있다.The cream modeling mask pack composition containing a chlorophyll derivative (Zn-Pheophytin) has an excellent moisturizing effect.
도1은 엽록소의 구조를 나타낸 그림도이다.
도2는 본 발명 엽록소 유도체(Zn-Pheophytin)가 함유된 크림 모델링 마스크팩의 제조 공정을 나타낸 다이어그램이다.
도3a 내지 3c는 본 발명에 따른 2종의 엽록소 유도체(Zn-Pheophytin)가 함유된 크림 모델링 마스크팩과 대조군 마스크팩의 경표피수분손실량을 측정한 결과를 나타낸 그래프이다.Fig. 1 is a diagram showing the structure of chlorophyll.
2 is a diagram showing a manufacturing process of a cream modeling mask pack containing a chlorophyll derivative (Zn-Pheophytin) of the present invention.
FIGS. 3A to 3C are graphs showing the results of measurement of moisture loss of light skin of a cream modeling mask pack and a control mask pack containing two kinds of chlorophyll derivatives (Zn-Pheophytin) according to the present invention.
본 발명은 엽록소 유도체(Zn-Pheophytin)가 함유된 크림 모델링 마스크팩 조성물을 제공한다.The present invention provides a cream modeling mask pack composition containing a chlorophyll derivative (Zn-Pheophytin).
본 발명에 따르면 상기 마스크팩 조성물은 엽록소 유도체(Zn-Pheophytin) 첨가시 보습원료인 Sodium Hyaluronate와 Sodium Polyglutamate를 각각 첨가하여 제조하였다.According to the present invention, the mask pack composition was prepared by adding sodium hyaluronate and sodium polyglutamate, which are the moisturizing raw materials, when the chlorophyll derivative (Zn-Pheophytin) was added.
본 발명에 따라 제조된 상기 마스크팩 조성물의 점도는 바람직하게는 35,000 내지 45,000 cps이고 가장 바람직하게는 40,000cps이다.The viscosity of the mask pack composition prepared according to the present invention is preferably 35,000 to 45,000 cps and most preferably 40,000 cps.
본 발명은 하기의 구체적인 실시예, 실험예에 의해 보다 구체적으로 설명되나, 하기 실시예, 실험예는 본 발명을 예시하기 위한 것으로 본 발명의 권리범위가 이에 한정하는 것으로 의도되지는 않는다.
The present invention will be described in more detail by way of the following specific examples and experimental examples. However, the following examples and experimental examples are intended to illustrate the present invention and are not intended to limit the scope of the present invention.
실시예1. 본 발명 엽록소 유도체(Zn-Pheophytin)가 함유된 크림 모델링 마스크팩(Cream modeling Mask) 제조.Example 1. Manufacture of a cream modeling mask containing a chlorophyll derivative (Zn-Pheophytin) of the present invention.
본 발명 엽록소 유도체(Zn-Pheophytin)가 함유된 크림 모델링 마스크팩을 제조하기 위해 파우더제와 크림제를 각각 제조하였다. 파우더제는 하기 표1의 성분들을 헨슬믹서에 첨가한 후 균일하게 혼합하여 수득하였다. To prepare a cream modeling mask pack containing the chlorophyll derivative (Zn-Pheophytin) of the present invention, a powder agent and a cream agent were respectively prepared. The powders were obtained by adding the components shown in Table 1 below to a Henschel mixer and mixing them uniformly.
이와 별도로 크림제는 하기 표2의 성분들을 첨가하여 수득하였다. 이를 위해 먼저 정제수에 점증제를 첨가한 후 점증여부를 확인하였고 나머지 원료들을 순차적으로 첨가하여 균일하게 분산시키고 엽록소 유도체(Zn-Pheophytin)를 첨가하여 40,000cps 이상이 되는지 점도를 확인하였다. 엽록소 유도체(Zn-Pheophytin) 첨가시 실험군은 보습원료인 Sodium Hyaluronate와 Sodium Polyglutamate를 각각 엽록소 유도체(Zn-Pheophytin)와 함께 첨가하였고, 대조군은 엽록소 유도체(Zn-Pheophytin) 없이 Sodium Polyglutamate만을 첨가하였다(도2).Separately, the cream formulations were obtained by adding the ingredients of Table 2 below. In order to do this, it was firstly added to the purified water, and then it was confirmed whether it was gradually increased or not. The remaining ingredients were added successively and uniformly dispersed and added with a chlorophyll derivative (Zn-Pheophytin) Sodium hyaluronate and sodium polyglutamate were added together with chlorophyll derivative (Zn-Pheophytin) and chlorophyll derivative (Zn-Pheophytin) was added to the experimental group. Sodium polyglutamate was added to the control group without chlorophyll derivative (Zn-Pheophytin) 2).
실험군1
실험군2Control group
Experiment 1
Experiment 2
실험예1. 임상실험(In vivo test).Experimental Example 1 In vivo test.
상기 실시예1에서 수득한 3종의 마스크팩의 보습효과 및 이상 여부를 확인하기 위해 Vapometer를 이용하여 경표피수분손실량(TEWL: Transepidermal Water Loss)을 측정하였다.In order to confirm the moisturizing effect and the abnormality of the three types of mask packs obtained in Example 1, a transepidermal water loss (TEWL) was measured using a vapometer.
이를 위해 만 19세~59세의 여성 20명을 대상으로 전박부위에 무도포부위 1곳과 도포부위 3곳을 4 x 6cm 크기로 선정하여 도포 전 피부 측정 및 상태를 확인하였고 전박 부위에 30분 동안 도포 후 제거한 다음 피부 이상 반응 여부를 확인하였다. 그 후 1시간, 3시간 및 6시간 경과 후 피부 측정 및 이상 반응을 확인하였다.For this purpose, 20 women aged 19 to 59 years old were selected as 4 x 6 cm size of one balloon area and three application areas on the whole bamboo area. And then skin irritation was confirmed. After 1, 3, and 6 hours thereafter, skin measurements and adverse events were observed.
실험 결과, 도3a 내지 도3c 및 하기 표3에서 알 수 있듯이 Sodium Polyglutamate만을 첨가한 대조군은 마스크팩 사용 전 TEWL이 8.10g/m2h이었으나 1시간 후 6.96g/m2h로 약 14%의 수분보유도가 증가하였고 Sodium Hyaluronate와 엽록소 유도체(Zn-Pheophytin)를 첨가한 실험군1은 도포 1시간 후 TEWL은 6.32g/m2h로 도포 전보다 약 23% 수분 보유 능력이 증가하였으며 3시간 및 6시간 후에도 대조군에 비해 약 12%와 7% 증가하였다. 또 Sodium Polyglutamate와 엽록소 유도체(Zn-Pheophytin)를 첨가한 실험군2는 1시간 경과 후 TEWL은 6.53g/m2h로 도포 전에 비해 약 21% 증가하였고 대조군에 비해서도 약 6% 증가하였다. 3시간 및 6시간 경과 후에는 대조군에 비해 약 3%, 1% 증가하였다.Experimental results about 14% to Figures 3a-3c, and as can be seen in Table 3 to the control group was added only Sodium Polyglutamate was 6.96g / m 2 h after the mask pack before use TEWL yieoteuna 8.10g / m 2 h 1 time Experimental group 1 containing sodium hyaluronate and chlorophyll derivative (Zn-Pheophytin) showed an increase in water retention, and TEWL was 6.32 g / m 2 h after 1 hour of application. And 12% and 7%, respectively, compared to the control group. Further Sodium Polyglutamate and experimental group was added to chlorophyll derivatives (Zn-Pheophytin) 2 1 hour after the TEWL is increased about 21% than that prior to application to 6.53g / m 2 h was increased by about 6% in the control group bihaeseodo. 3 and 1% after 3 and 6 hours, respectively.
결론적으로 임상실험을 통한 TEWL 측정 결과 Sodium Hyaluronate와 엽록소 유도체(Zn-Pheophytin)를 첨가한 실험군1에서 가장 우수한 보습력을 확인하였다.
In conclusion, TEWL measurement by clinical experiment showed the best moisture-holding ability in Experimental Group 1 with addition of sodium hyaluronate and chlorophyll derivative (Zn-Pheophytin).
이상 설명한 바와 같이 본 발명 엽록소 유도체(Zn-Pheophytin)가 함유된 크림 모델링 마스크팩 조성물은 보습 개선 기능성이 뛰어난 효과가 있으므로 화장료 산업상 매우 유용한 발명인 것이다.As described above, the cream modeling mask pack composition containing the chlorophyll derivative (Zn-Pheophytin) of the present invention is an extremely useful invention in the cosmetic industry because it has an excellent moisturizing and improving function.
Claims (3)
이와 별도로 계량한 정제수에 점증제 Algin을 첨가하고 균일하게 혼합하는 단계와; 상기 단계에서 얻은 혼합물에 Butylene Glycol, Algin, PEG-60 Hydrogenated Castor Oil, 1,2-Hexanediol, Ethylhexylglycerin, Disodium EDTA 및 보습제인 Sodium Hyaluronate 또는 Sodium Polyglutamate를 첨가한 후 균일하게 분산시키는 단계와; 상기 단계에서 얻은 혼합물에 엽록소 유도체 (Zn-Pheophytin)를 첨가하여 분산한 후 점도가 40,000cps 이상인 크림제를 수득하는 단계로 통해 제조한 엽록소 유도체 (Zn-Pheophytin)가 함유된 크림 모델링 마스크팩 제조방법.
Glucose, Calcium Sulfate, Diatomaceous Earth, Silica and Tetrapotassium Pyrophosphate are placed in a Handsmixer, mixed and stirred to obtain a powder agent;
Adding Algin to the purified water separately measured and mixing it uniformly; Adding uniformly dispersed Butylene Glycol, Algin, PEG-60 Hydrogenated Castor Oil, 1,2-Hexanediol, Ethylhexylglycerin, Disodium EDTA and Sodium Hyaluronate or Sodium Polyglutamate as a moisturizing agent to the mixture obtained in the above step; A method for producing a cream modeling mask pack containing a chlorophyll derivative (Zn-Pheophytin) prepared by the step of adding a chlorophyll derivative (Zn-Pheophytin) to the mixture obtained in the above step and dispersing the mixture to obtain a cream agent having a viscosity of 40,000 cps or more .
A cream modeling mask pack containing the composition of claim 2.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170003965A KR101940896B1 (en) | 2017-01-11 | 2017-01-11 | Cream modeling mask pack for epidermal moisturing composition comprising chlorophyll derivatives and preparation method of the same |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020170003965A KR101940896B1 (en) | 2017-01-11 | 2017-01-11 | Cream modeling mask pack for epidermal moisturing composition comprising chlorophyll derivatives and preparation method of the same |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20180082734A true KR20180082734A (en) | 2018-07-19 |
| KR101940896B1 KR101940896B1 (en) | 2019-01-22 |
Family
ID=63058468
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020170003965A Active KR101940896B1 (en) | 2017-01-11 | 2017-01-11 | Cream modeling mask pack for epidermal moisturing composition comprising chlorophyll derivatives and preparation method of the same |
Country Status (1)
| Country | Link |
|---|---|
| KR (1) | KR101940896B1 (en) |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20060110491A (en) * | 2005-04-20 | 2006-10-25 | 노석 | Cosmetic composition for a massage pack in the form of a gel and a method of manufacturing the same |
| US20100255045A1 (en) * | 2007-11-27 | 2010-10-07 | Eymard Du Vernet Michele | Composition for photodynamic skin treatment |
-
2017
- 2017-01-11 KR KR1020170003965A patent/KR101940896B1/en active Active
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20060110491A (en) * | 2005-04-20 | 2006-10-25 | 노석 | Cosmetic composition for a massage pack in the form of a gel and a method of manufacturing the same |
| US20100255045A1 (en) * | 2007-11-27 | 2010-10-07 | Eymard Du Vernet Michele | Composition for photodynamic skin treatment |
Also Published As
| Publication number | Publication date |
|---|---|
| KR101940896B1 (en) | 2019-01-22 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101333209B1 (en) | Cosmetic composition for preventing skin aging comprising surface-modified gold nanoparticle by phytochemical | |
| WO2008140200A1 (en) | External compositions for the skin | |
| KR20090098732A (en) | Anti-inflammatory, antioxidant or antibacterial composition | |
| KR102047214B1 (en) | Composition for scalp care and manufacturing method thereof | |
| US7132118B2 (en) | Cucumis melo extract coated and/or microencapsulated in a fat-soluble agent based on a fatty substance | |
| KR20170092293A (en) | Cosmetic Composition Containing Fermented Extract from Lycium Chinense and Manufacturing Method Thereof | |
| KR20170112745A (en) | Cosmetic composition for improving acne containing teatree leaves spicule powder | |
| KR20190035086A (en) | Skin external composition containing 1,2,3,4,6-penta-O-galloyl-β-D-glucose for skin moisturizing | |
| KR101940896B1 (en) | Cream modeling mask pack for epidermal moisturing composition comprising chlorophyll derivatives and preparation method of the same | |
| KR101761005B1 (en) | Cosmetic composition containing non-toxic sulfur for sikn moisture, anti-inflammatory and immune enhancement and manufacturing the same | |
| KR101893970B1 (en) | Cosmetic composition containing Resveratrol | |
| CN114452435B (en) | High-affinity liquid dressing capable of being rapidly effective | |
| KR20210105233A (en) | Cream formulation mask pack for improving acne comprising chlorophyll derivatives and preparation method of the same | |
| KR101208120B1 (en) | Vitamin complex, preparation methods and cosmetic composition comprising thereof | |
| RU2089177C1 (en) | Agent for skin care | |
| KR101501554B1 (en) | cosmetic composition including 70kDa protein from silkworm larvae hemolymph | |
| KR102066821B1 (en) | Natural Complex Cosmetic Preservative Composition | |
| KR20180110357A (en) | Cosmetic composition for preventing oxidative stress comprising nephrite water and nephrite powder | |
| KR102024167B1 (en) | Skin temperature sensitive gel composition comprising bee venom and mask pack using the same | |
| KR20230065023A (en) | Cosmetic composition for skin improvement comprising natural products from Jeju | |
| KR101404460B1 (en) | Cosmetics composition comprising fish extract | |
| KR20110103631A (en) | Ocher soap provided with a mixture of ocher and functional ingredients | |
| JP4586178B2 (en) | External preparation for improving skin damaged by burns | |
| KR20170047515A (en) | Skin vital rising cosmetic composition comprising Graviola antibiotic extract and method of preparing the same | |
| KR101905005B1 (en) | Cosmetic composition for acne improvement comprising myrciaria dubia, malpighia emarginata and sophora japonica extract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| PA0109 | Patent application |
Patent event code: PA01091R01D Comment text: Patent Application Patent event date: 20170111 |
|
| PA0201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| PE0902 | Notice of grounds for rejection |
Comment text: Notification of reason for refusal Patent event date: 20180612 Patent event code: PE09021S01D |
|
| PG1501 | Laying open of application | ||
| E701 | Decision to grant or registration of patent right | ||
| PE0701 | Decision of registration |
Patent event code: PE07011S01D Comment text: Decision to Grant Registration Patent event date: 20181218 |
|
| GRNT | Written decision to grant | ||
| PR0701 | Registration of establishment |
Comment text: Registration of Establishment Patent event date: 20190115 Patent event code: PR07011E01D |
|
| PR1002 | Payment of registration fee |
Payment date: 20190115 End annual number: 3 Start annual number: 1 |
|
| PG1601 | Publication of registration | ||
| PR1001 | Payment of annual fee |
Payment date: 20211228 Start annual number: 4 End annual number: 4 |
|
| PR1001 | Payment of annual fee |
Payment date: 20230103 Start annual number: 5 End annual number: 5 |
|
| PR1001 | Payment of annual fee |
Payment date: 20240104 Start annual number: 6 End annual number: 6 |
|
| PR1001 | Payment of annual fee |
Payment date: 20250203 Start annual number: 7 End annual number: 7 |